Forest Laboratories, Inc. to Present Cariprazine Results from a Phase 3 Trial and Two Pharmacology Studies at the American College of Neuropsychopharmacology (ACNP) Annual Meeting Business Wire NEW YORK -- December 03, 2012 Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on cariprazine at the American College of Neuropsychopharmacology Annual Meeting scheduled December 2-6, 2012 in Hollywood, FL. Forest Laboratories, Inc recently submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for cariprazine for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with Bipolar I disorder. The cariprazine results will be announced in 3 poster presentations: *Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: A Phase III, International, Randomized, Double-blind, Placebo-controlled Trial (Poster 9: Wednesday, December 5 from 5:30 pm - 7:30 pm EST) *Cariprazine Exhibits Dopamine D Receptor-Dependent Antidepressant-Like Activity in the Chronic Unpredictable Stress Model of Anhedonia (Poster 12:Monday, December 3 from 5:30 pm - 7:30 pm EST) *Effects of Chronic Cariprazine Administration on Serotonin and Glutamate Receptor Subtypes (Poster 161:Monday, December 3 from 5:30 pm - 7:30 pm EST) About Cariprazine Cariprazine is an orally active and potent dopamine D-preferring D[3 ]/D receptor partial agonist. Cariprazine has a low affinity at other receptor sites such as 5-HT[2C], muscarinic, and adrenergic which have been associated with adverse events. Cariprazine was discovered by Gedeon Richter Plc and is licensed to Forest Laboratories Inc., in the U.S. and Canada. About Gedeon Richter Plc. Gedeon Richter Plc. (www.richter.hu) headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter’s consolidated sales wereapproximately EUR 1.1 billion (USD 1.5 billion) while its market capitalization amounted to EUR 2.1 billion (USD 2.7 billion) in 2011. The product portfolio of the Company covers almost all important therapeutic areas, including gynecology, central nervous system and cardiovascular. Having the largest R&D unit in Central Eastern Europe, the Company’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise Richter is a significant player in the female healthcare field worldwide. Richter is also active in the scope of biosimilar product development. About Forest Laboratories Forest Laboratories’ (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective and respiratory, gastrointestinal, and pain management medicine. The Company’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com. Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to update forward looking statements contained in this release to reflect new information or future events or developments. Contact: Forest Laboratories, Inc. Frank J. Murdolo, 212-224-6714 Vice President - Investor Relations Frank.Murdolo@frx.com
Forest Laboratories, Inc. to Present Cariprazine Results from a Phase 3 Trial and Two Pharmacology Studies at the American
Press spacebar to pause and continue. Press esc to stop.